TICKERNERD
Menu
INMBINMBHealthcare · Biotechnology

INMB Stock Forecast: INmune Bio, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$1.94
+0.52% on the day

The 4 Wall Street analysts covering INmune Bio, Inc. hold a median 12-month price target of $7.5 — +286.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$53.6M
Ticker Nerd rank
53 / 100
Median analyst target
$7.50
Analysts covering
4
Revenue$0.0
Operating income−$1.5M
Net income−$1.3M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−20.5%
YTD
+24.4%
1Y
−6.7%
From 52W high
−22.7%
From 52W low
+73.2%
$1.12
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INMB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
81
Revisions
65
Momentum
55
Accruals
46
Value
43
Volatility
36
Quality
33
Issuance
19

Growth (86): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26INMBHigh $9.00Median $7.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $4.00Median $7.50High $9.00

The green dot is the last close — the median target sits +286.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Mar 2026LUCID CAPITAL MARKETSUpgradeBuy$2.00 → $9.00
2 July 2025Maxim GroupMaintainsBuy—
1 July 2025BTIGDowngradeNeutral—
1 July 2025ScotiabankDowngradeSector Underperform—
13 Feb 2025Maxim GroupMaintainsBuy—
11 Feb 2025ScotiabankMaintainsSector Outperform—
21 Oct 2024Alliance Global PartnersInitiatesBuy$20
27 Sept 2024Raymond JamesInitiatesOutperform$18
22 Aug 2024ScotiabankInitiatesSector Outperform$22
1 June 2023BairdInitiatesOutperform—
24 May 2022B. Riley SecuritiesDowngradeNeutral—
24 May 2022BTIGMaintainsBuy—
24 Jan 2022B. Riley SecuritiesMaintainsBuy—
21 Apr 2021B. Riley FBRInitiatesBuy—
21 Apr 2021B. Riley SecuritiesInitiatesBuy—
25 Nov 2020BTIGInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020HC Wainwright & Co.MaintainsBuy—
25 Nov 2020Maxim GroupInitiatesBuy—
25 Nov 2020Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INMB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, INmune Bio, Inc. returned −6.7% against +16.2% for the S&P 500, dividends included.

INMB vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26INMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

INmune Bio, Inc. (INMB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 83% of US stocks

Price / sales
1071.3×

Cheaper than 1% of US stocks

Price / book
2.6×

Cheaper than 36% of US stocks

EV / EBITDA
−2.6×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−61738.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−74.8%

Higher than 17% of US stocks

Return on assets
−39.1%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

INmune Bio, Inc. (INMB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • INmune Bio, Inc. has a market value of $53.6M and an enterprise value of $36.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.7M.

  • Shares outstanding: 27.7M.

  • Trailing P/E: −1.0×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • INmune Bio, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

INMB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INMBINmune Bio, Inc.$53.6M
53
CELUCelularity, Inc.$51.9M
30
EDSAEdesa Biotech, Inc.$52.2M
50
ELTXElicio Therapeutics, Inc.$50.5M
38
ANVSAnnovis Bio, Inc.$50.2M
27
SERSerina Therapeutics, Inc.$49.8M
19
DWTXDogwood Therapeutics, Inc.$49.6M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INMB news & analysis

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

GlobeNewsWire · 14 Sept 2026positive

INmune Bio announced the appointment of a Sanofi rare-disease executive and a biopharma business development leader to its board. The appointments are intended to strengthen the company's rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel advances toward potential commercialization.

Why it matters — The new board members bring expertise in rare-disease commercialization and business development, which could support INmune Bio's preparations as Ebstrocel moves closer to potential commercialization.

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

GlobeNewsWire · 9 Sept 2026neutral

INmune Bio announced it will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET).

Why it matters — INMB watchers would care because the conference presentation offers an opportunity for the company to communicate its progress to the investment community.

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

Seeking Alpha · 28 Aug 2026positive

The article discusses INmune Bio's candidate Ebstrocel for recessive dystrophic epidermolysis bullosa (RDEB), noting potential UK regulatory alignment and positioning for UK, EU, and US regulatory filings by early 2027. It highlights Ebstrocel's systemic itch reduction as a differentiator from competitors.

Why it matters — INMB watchers would care because the reported regulatory alignment and anticipated filing milestones for Ebstrocel could be a key catalyst for the company's valuation.

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

GlobeNewsWire · 26 Aug 2026positive

INmune Bio has submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB). These filings support a planned European marketing authorization application in Q1 2027.

Why it matters — A watcher of INMB would care because advancing Ebstrocel™ toward European marketing authorization could, if orphan designation is granted and maintained, bring regulatory incentives including 10 years of market exclusivity.

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

INmune Bio Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the company's financial results and management commentary for the quarter.

Why it matters — The earnings call transcript provides INMB watchers with direct insight into the company's quarterly performance and management's stated outlook.

FAQ

Frequently asked questions about INMB stock

What is the INMB stock price forecast for 2026-2027?

The 4 Wall Street analysts covering INmune Bio, Inc. have a median 12-month price target of $7.5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INMB stock a buy right now?

Of the 4 analysts covering INmune Bio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 53 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INMB?

As at 3 Oct 2026, INmune Bio, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will INMB stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +286.6% from the last close, and Ticker Nerd's factor model ranks INmune Bio, Inc. 53 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INMB stock forecast for 2030?

No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has INMB stock performed over the past year?

INmune Bio, Inc. returned -6.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does INmune Bio, Inc. do?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases.

What is the latest news on INMB?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board". INmune Bio announced the appointment of a Sanofi rare-disease executive and a biopharma business development leader to its board. The appointments are intended to strengthen the company's rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel advances toward potential commercialization.

Company

About INmune Bio, Inc.

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.

CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com